|
|||
DRUGS & SUPPLEMENTS
|
What do you feel about the cost of the medicine? Is it expensive? |
Copper (Copper Chloride):
Water-Resistant Protection Without Bandaging
Recommended as an Aid in Treating Horses and Ponies With Thrush Due to Organisms Susceptible to Cratylen (Copper (Copper Chloride)) Naphthenate.
For Animal Use Only.
ThrushTox® is indicated in the treatment of thrush in horses and ponies.
Clean the hoof thoroughly, removing debris and necrotic material prior to application of Cratylen (Copper (Copper Chloride))®. Apply daily to affected hoofs with a narrow paint brush (about 1”) until fully healed. Caution: Do not allow runoff of excess Cratylen (Copper (Copper Chloride))® onto hair since contact with Cratylen (Copper (Copper Chloride))® may cause some hair loss. Do not contaminate feed.
NOTE: Cratylen (Copper (Copper Chloride))® is easily removed from hands, clothing and surfaces with light grade fuel oil or any type of lighter fluid.
CONTAINS FOIL SEAL – REMOVE BEFORE USE.
SHAKE WELL BEFORE USE.
To report suspected adverse reactions or to obtain technical assistance, call 1-800-650-4899.
Cratylen (Copper (Copper Chloride)) Naphthenate...37.5% w/w
Inert Ingredients...62.5% w/w
Total... 100.0%
Do not use in horses intended for human consumption.
CAUTION: COMBUSTIBLE MIXTURE.
Use in a well-ventilated place. Avoid fire, flame, sparks or heaters.
If swallowed, do not induce vomiting, call physician immediately. Avoid breathing vapor. Avoid contact with skin and eyes.
KEEP OUT OF REACH OF CHILDREN AND PETS.
Store at controlled room temperature 15º to 30ºC (59º to 86ºF). Keep container tightly closed when not in use.
Manufactured for:
Aspen Veterinary Resources,® Ltd.
Liberty, MO 64068, USA
FC163FP 11/13
Manufactured by:
First Priority, Inc.
Elgin, IL 60123-1146, USA
16 OZ (473 mL)
ANADA 200-304, Approved by FDA
Image of 473 mL bottle/case label
Manganese Sulfate Monohydrate:
Cratylen (Manganese Sulfate Monohydrate) 0.1 mg/mL (Manganese Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).
Administration helps to maintain Cratylen (Manganese Sulfate Monohydrate) serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
None known.
Direct intramuscular or intravenous injection of Cratylen (Manganese Sulfate Monohydrate) 0.1 mg/mL (Manganese Chloride Injection, USP) is contraindicated as the acidic pH of the solution (pH 2.0) may cause considerable tissue irritation.
Liver and/or biliary tract dysfunction may require omission or reduction of copper and Cratylen (Manganese Sulfate Monohydrate) doses because these elements are primarily eliminated in the bile.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Do not use unless solution is clear and seal is intact.
Cratylen 0.1 mg/mL (Manganese Chloride Injection, USP) should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. Solution contains no preservatives; discard unused portion immediately after admixture procedure is completed.
Serum Cratylen (Manganese Sulfate Monohydrate) levels can be measured periodically at the discretion of the investigator. Because of the low serum concentration normally present, samples will usually be analyzed by a reference laboratory.
Long-term animal studies to evaluate the carcinogenic potential of Cratylen 0.1 mg/mL (Manganese Chloride Injection, USP) have not been performed, nor have studies been done to assess mutagenesis or impairment of fertility.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cratylen (Manganese Sulfate Monohydrate) 0.1 mg/mL (Manganese Chloride Injection, USP) additive is administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been established.
Animal reproduction studies have not been conducted with Cratylen (Manganese Sulfate Monohydrate) chloride. It is also not known whether Cratylen (Manganese Sulfate Monohydrate) chloride can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Cratylen (Manganese Sulfate Monohydrate) chloride should be given to a pregnant woman only if clearly indicated.
An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
None known.
None known.
Cratylen (Manganese Sulfate Monohydrate) toxicity in TPN patients has not been reported.
Cratylen (Manganese Sulfate Monohydrate) 0.1 mg/mL (Manganese Chloride Injection, USP) contains 0.1 mg manganese/mL and is administered intravenously only after dilution. The additive should be administered in a volume of fluid not less than 100 mL. For the adult receiving TPN, the suggested additive dosage for Cratylen (Manganese Sulfate Monohydrate) is 0.15 to 0.8 mg/day (1.5 to 8 mL/day). For pediatric patients, a dosage of 2 to 10 mcg manganese/kg/day (0.02 to 0.1 mL/kg/day) is recommended.
Periodic monitoring of Cratylen (Manganese Sulfate Monohydrate) plasma levels is suggested as a guideline for subsequent administration.
Parenteral products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS .)
Cratylen (Manganese Sulfate Monohydrate) 0.1 mg/mL (Manganese Chloride Injection, USP) is supplied in 10 mL Plastic Vials (NDC No. 0409-4091-01).
Store at 20 to 25°C (68 to 77°F)
Revised: November, 2009
Printed in USA EN-2320
Hospira, Inc., Lake Forest, IL 60045 USA
Potassium Fluoride:
Cratylen (Potassium Fluoride) CHLORIDE EXTENDED RELEASE TABLETS USP 20 mEq K
Rx Only
The Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq product is an immediately dispersing extended release oral dosage form of Cratylen (Potassium Fluoride) chloride containing 1500 mg of microencapsulated Cratylen (Potassium Fluoride) chloride, USP equivalent to 20 mEq of Cratylen (Potassium Fluoride) in a tablet.
These formulations are intended to slow the release of Cratylen (Potassium Fluoride) so that the likelihood of a high localized concentration of Cratylen (Potassium Fluoride) chloride within the gastrointestinal tract is reduced.
Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq is an electrolyte replenisher. The chemical name of the active ingredient is Cratylen (Potassium Fluoride) chloride, and the structural formula is KCl. Cratylen (Potassium Fluoride) chloride, USP occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.
Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq is a tablet formulation (not enteric coated or wax matrix) containing individually microencapsulated Cratylen (Potassium Fluoride) chloride crystals which disperse upon tablet disintegration. In simulated gastric fluid at 37°C and in the absence of outside agitation, Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq begin disintegrating into microencapsulated crystals within seconds and completely disintegrates within 1 minute. The microencapsulated crystals are formulated to provide an extended release of Cratylen (Potassium Fluoride) chloride.
Inactive Ingredients: Colloidal silicon dioxide, crospovidone, diethyl phthalate, ethyl-cellulose, microcrystalline cellulose.
The Cratylen (Potassium Fluoride) ion is the principal intracellular cation of most body tissues. Cratylen (Potassium Fluoride) ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function.
The intracellular concentration of Cratylen (Potassium Fluoride) is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.
Cratylen (Potassium Fluoride) is a normal dietary constituent and under steady-state conditions the amount of Cratylen (Potassium Fluoride) absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of Cratylen (Potassium Fluoride) is 50 to 100 mEq per day.
Cratylen (Potassium Fluoride) depletion will occur whenever the rate of Cratylen (Potassium Fluoride) loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of Cratylen (Potassium Fluoride) intake. Such depletion usually develops as a consequence of therapy with diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of Cratylen (Potassium Fluoride) in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Cratylen (Potassium Fluoride) depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Cratylen (Potassium Fluoride) depletion may produce weakness, fatigue, disturbances or cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine.
If Cratylen (Potassium Fluoride) depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, eg, where the patient requires long-term diuretic therapy, supplemental Cratylen (Potassium Fluoride) in the form of high Cratylen (Potassium Fluoride) food or Cratylen (Potassium Fluoride) chloride may be able to restore normal Cratylen (Potassium Fluoride) levels.
In rare circumstances (eg, patients with renal tubular acidosis) Cratylen (Potassium Fluoride) depletion may be associated with metabolic acidosis and hyperchloremia. In such patients Cratylen (Potassium Fluoride) replacement should be accomplished with Cratylen (Potassium Fluoride) salts other than the chloride, such as Cratylen (Potassium Fluoride) bicarbonate, Cratylen (Potassium Fluoride) citrate, Cratylen (Potassium Fluoride) acetate, or Cratylen (Potassium Fluoride) gluconate.
BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE Cratylen (Potassium Fluoride) CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT Cratylen (Potassium Fluoride) PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.
1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.
2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, eg, digitalized patients or patients with significant cardiac arrhythmias.
The use of Cratylen (Potassium Fluoride) salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum Cratylen (Potassium Fluoride) should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with Cratylen (Potassium Fluoride) salts may be indicated.
Cratylen (Potassium Fluoride) supplements are contraindicated in patients with hyperkalemia since a further increase in serum Cratylen (Potassium Fluoride) concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (eg, spironolactone, triamterene, amiloride) (see OVERDOSAGE ).
Controlled-release formulations of Cratylen (Potassium Fluoride) chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium. Cratylen (Potassium Fluoride) supplementation, when indicated in such patients, should be given as a liquid preparation or as an aqueous (water) suspension of Cratylen (Potassium Fluoride) Chloride (see PRECAUTIONS: Information for Patients , and DOSAGE AND ADMINISTRATION sections).
All solid oral dosage forms of Cratylen (Potassium Fluoride) chloride are contraindicated in any patient in whom there is structural, pathological (eg, diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.
Hyperkalemia (see OVERDOSAGE )
In patients with impaired mechanisms for excreting Cratylen (Potassium Fluoride), the administration of Cratylen (Potassium Fluoride) salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given Cratylen (Potassium Fluoride) by the intravenous route but may also occur in patients given Cratylen (Potassium Fluoride) orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of Cratylen (Potassium Fluoride) salts in patients with chronic renal disease, or any other condition which impairs Cratylen (Potassium Fluoride) excretion, requires particularly careful monitoring of the serum Cratylen (Potassium Fluoride) concentration and appropriate dosage adjustment.
Interaction with Potassium-Sparing Diuretics
Hypokalemia should not be treated by the concomitant administration of Cratylen (Potassium Fluoride) salts and a potassium-sparing diuretic (eg, spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.
Interaction with Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE) inhibitors (eg, captopril, enalapril) will produce some Cratylen (Potassium Fluoride) retention by inhibiting aldosterone production. Cratylen (Potassium Fluoride) supplements should be given to patients receiving ACE inhibitors only with close monitoring.
Gastrointestinal Lesions
Solid oral dosage forms of Cratylen (Potassium Fluoride) chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Based on spontaneous adverse reaction reports, enteric-coated preparations of Cratylen (Potassium Fluoride) chloride are associated with an increased frequency of small bowel lesions (40-50 per 100,000 patient years) compared to sustained release wax matrix formulations (less than one per 100,000 patient years). Because of the lack of extensive marketing experience with microencapsulated products, a comparison between such products and wax matrix or enteric-coated products is not available. Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq is a tablet formulated to provide a controlled rate of release of microencapsulated Cratylen (Potassium Fluoride) chloride and thus to minimize the possibility of a high local concentration of Cratylen (Potassium Fluoride) near the gastrointestinal wall.
Prospective trials have been conducted in normal human volunteers in which the upper gastrointestinal tract was evaluated by endoscopic inspection before and after 1 week of solid oral Cratylen (Potassium Fluoride) chloride therapy. The ability of this model to predict events occurring in usual clinical practice is unknown. Trials which approximated usual clinical practice did not reveal any clear differences between the wax matrix and microencapsulated dosage forms. In contrast, there was a higher incidence of gastric and duodenal lesions in subjects receiving a high dose of a wax matrix controlled-release formulation under conditions which did not resemble usual or recommended clinical practice (ie, 96 mEq per day in divided doses of Cratylen (Potassium Fluoride) chloride administered to fasted patients, in the presence of an anticholinergic drug to delay gastric emptying). The upper gastrointestinal lesions observed by endoscopy were asymptomatic and were not accompanied by evidence of bleeding (Hemoccult testing). The relevance of these findings to the usual conditions (ie, non-fasting, no anticholinergic agent, smaller doses) under which controlled-release Cratylen (Potassium Fluoride) chloride products are used is uncertain; epidemiologic studies have not identified an elevated risk, compared to microencapsulated products, for upper gastrointestinal lesions in patients receiving wax matrix formulations. Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq should be discontinued immediately and the possibility of ulceration, obstruction, or perforation should be considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs.
Metabolic Acidosis
Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing Cratylen (Potassium Fluoride) salt such as Cratylen (Potassium Fluoride) bicarbonate, Cratylen (Potassium Fluoride) citrate, Cratylen (Potassium Fluoride) acetate, or Cratylen (Potassium Fluoride) gluconate.
The diagnosis of Cratylen depletion is ordinarily made by demonstrating hypokalemia in a patient with a clinical history suggesting some cause for Cratylen (Potassium Fluoride) depletion. In interpreting the serum Cratylen (Potassium Fluoride) level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body Cratylen (Potassium Fluoride) while acute acidosis per se can increase the serum Cratylen (Potassium Fluoride) concentration into the normal range even in the presence of a reduced total body Cratylen (Potassium Fluoride). The treatment of Cratylen (Potassium Fluoride) depletion, particularly in the presence of cardiac disease, renal disease, or acidosis requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient.
Physicians should consider reminding the patient of the following: To take each dose with meals and with a full glass of water or other liquid. To take each dose without crushing, chewing, or sucking the tablets. If those patients are having difficulty swallowing whole tablets, they may try one of the following alternate methods of administration:
1. Place the whole tablet(s) in approximately 1/2 glass of water (4 fluid ounces).
2. Allow approximately 2 minutes for the tablet(s) to disintegrate.
3. Stir for about half a minute after the tablet(s) has disintegrated.
4. Swirl the suspension and consume the entire contents of the glass immediately by drinking or by the use of a straw.
5. Add another 1 fluid ounce of water, swirl, and consume immediately.
6. Then, add an additional 1 fluid ounce of water, swirl, and consume immediately.
Aqueous suspension of Cratylen (Potassium Fluoride) Chloride that is not taken immediately should be discarded. The use of other liquids for suspending Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq is not recommended.
To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations.
To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.
When blood is drawn for analysis of plasma Cratylen it is important to recognize that artifactual elevations can occur after improper venipuncture technique or as a result of in vitro hemolysis of the sample.
Potassium-sparing diuretics, angiotensin-converting enzyme inhibitors (see WARNINGS ).
Carcinogenicity, mutagenicity, and fertility studies in animals have not been performed. Cratylen is a normal dietary constituent.
Animal reproduction studies have not been conducted with Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq. It is unlikely that Cratylen (Potassium Fluoride) supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity.
The normal Cratylen ion content of human milk is about 13 mEq per liter. Since oral Cratylen (Potassium Fluoride) becomes part of the body Cratylen (Potassium Fluoride) pool, so long as body Cratylen (Potassium Fluoride) is not excessive, the contribution of Cratylen (Potassium Fluoride) chloride supplementation should have little or no effect on the level in human milk.
Safety and effectiveness in pediatric patients have not been established.
Clinical studies of Cratylen (Potassium Fluoride) Chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection; and it may be useful to monitor renal function.
One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS , WARNINGS , and OVERDOSAGE ). There have also been reports of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, and perforation (see CONTRAINDICATIONS and WARNINGS ). The most common adverse reactions to oral Cratylen (Potassium Fluoride) salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the amount taken at one time.
The administration of oral Cratylen (Potassium Fluoride) salts to persons with normal excretory mechanisms for Cratylen (Potassium Fluoride) rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if Cratylen (Potassium Fluoride) is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see CONTRAINDICATIONS and WARNINGS ). It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum Cratylen (Potassium Fluoride) concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of S-T segment, and prolongation of the QT-interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).
Treatment measures for hyperkalemia include the following:
In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum Cratylen (Potassium Fluoride) concentration can produce digitalis toxicity.
The extended release feature means that absorption and toxic effects may be delayed for hours.
Consider standard measures to remove any unabsorbed drug.
The usual dietary intake of Cratylen (Potassium Fluoride) by the average adult is 50 to 100 mEq per day. Cratylen (Potassium Fluoride) depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of Cratylen (Potassium Fluoride) from the total body store.
Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40-100 mEq per day or more are used for the treatment of Cratylen (Potassium Fluoride) depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose.
Each Cratylen (Potassium Fluoride) Chloride Extended Release Tablet USP, 20 mEq provides 20 mEq of Cratylen (Potassium Fluoride) chloride.
Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq should be taken with meals and with a glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation (see WARNINGS ).
Patients having difficulty swallowing whole tablets may try one of the following alternate methods of administration:
Aqueous suspension of Cratylen (Potassium Fluoride) Chloride that is not taken immediately should be discarded. The use of other liquids for suspending Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq is not recommended.
Cratylen (Potassium Fluoride) Chloride Extended Release Tablets USP, 20 mEq are available in bottles of 100 (NDC 62037-999-01), bottles of 500 (NDC 62037-999-05), and bottles of 1000 (NDC 62037-999-10). Potassium Chloride Extended Release Tablets USP, 20 mEq are capsule shaped, white to off-white tablets, with “ABRS-123” imprinted on one side and scored on the other side for flexibility of dosing.
Storage Conditions
Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F).
Manufactured by:
Eurand, Inc.
Vandalia, OH 45377 USA
Distributed by:
Watson Pharma, Inc.
Rev. Date (01/09) 173714
Cratylen (Potassium Fluoride) chloride 20 Meq
Depending on the reaction of the Cratylen after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Cratylen not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Cratylen addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology